Oncologic and reproductive outcomes of fertility-sparing surgery for borderline ovarian tumors: first presentation of 10-year experience from a Serbian referral center

Authors

  • Ivana Likić Lađević 1. Faculty of Medicine, University of Belgrade, Department for Gynecology and Obstetrics, Dr Subotića Starijeg 8, 11000 Belgrade, Serbia; 2. Clinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Dr Koste Todorovića 26, 11000 Belgrade, Serbia https://orcid.org/0000-0001-9743-2528
  • Dejan Nešić Institute of Medical Physiology, Faculty of Medicine, University of Belgrade, Višegradska 26/II, 11000 Belgrade, Serbia https://orcid.org/0000-0002-7794-3520
  • Aleksandar Stefanović 1. Faculty of Medicine, University of Belgrade, Department for Gynecology and Obstetrics, Dr Subotića Starijeg 8, 11000 Belgrade, Serbia; 2. Clinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Dr Koste Todorovića 26, 11000 Belgrade, Serbia https://orcid.org/0000-0002-3286-6007
  • Saša Kadija 1. Faculty of Medicine, University of Belgrade, Department for Gynecology and Obstetrics, Dr Subotića Starijeg 8, 11000 Belgrade, Serbia; 2. Clinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Dr Koste Todorovića 26, 11000 Belgrade, Serbia https://orcid.org/0000-0002-4992-1164
  • Zoran Vilendečić 1. Faculty of Medicine, University of Belgrade, Department for Gynecology and Obstetrics, Dr Subotića Starijeg 8, 11000 Belgrade, Serbia; 2. Clinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Dr Koste Todorovića 26, 11000 Belgrade, Serbia https://orcid.org/0000-0002-4992-1164
  • Igor Pilić 1. Faculty of Medicine, University of Belgrade, Department for Gynecology and Obstetrics, Dr Subotića Starijeg 8, 11000 Belgrade, Serbia; 2. Clinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Dr Koste Todorovića 26, 11000 Belgrade, Serbia https://orcid.org/0000-0003-2200-4339
  • Jelena Dotlić 1. Faculty of Medicine, University of Belgrade, Department for Gynecology and Obstetrics, Dr Subotića Starijeg 8, 11000 Belgrade, Serbia; 2. Clinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Dr Koste Todorovića 26, 11000 Belgrade, Serbia https://orcid.org/0000-0001-9683-9561
  • Miloš Radojević 1. Faculty of Medicine, University of Belgrade, Department for Gynecology and Obstetrics, Dr Subotića Starijeg 8, 11000 Belgrade, Serbia; 2. Clinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Dr Koste Todorovića 26, 11000 Belgrade, Serbia https://orcid.org/0000-0002-1097-754X
  • Branislav Milošević Clinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Dr Koste Todorovića 26, 11000 Belgrade, Serbia https://orcid.org/0000-0002-1994-8825
  • Katarina Stefanović 1. Faculty of Medicine, University of Belgrade, Department for Gynecology and Obstetrics, Dr Subotića Starijeg 8, 11000 Belgrade, Serbia; 2. Clinic for Obstetrics and Gynecology, University Clinical Centre of Serbia, Dr Koste Todorovića 26, 11000 Belgrade, Serbia

DOI:

https://doi.org/10.2298/ABS220722027L

Keywords:

borderline ovarian tumors, radical surgery, fertility sparing surgery, oncologic outcome, reproductive outcome

Abstract

Paper description:

  • Most borderline ovarian tumor patients are motivated to preserve fertility, with the safety and reproductive outcomes of fertility-sparing treatment being of concern.
  • Medical records of stage I borderline ovarian tumors treated and followed up in our institution for 10 years were analyzed.
  • In total, 52 patients were followed for a mean of 73.42 months, out of which 45 underwent fertility-sparing treatment. The overall survival rate was 100%. The recurrence rate was 7.7%; 64.4% attempted to achieve pregnancy, and the pregnancy success rate was 44.8%.
  • The fertility-sparing treatment in stage I borderline ovarian tumor is safe with a satisfactory oncological and reproductive outcome.

Abstract: The study aimed to assess the oncologic and reproductive outcome of fertility-sparing treatment of stage I borderline ovarian tumors (BOTs). A retrospective study of patients aged 18-40 years with stage I BOTs surgically treated during a 10-year period was conducted. In total, 52 patients (average age 32.7+/-5.9) were followed for 16 to 137 months after BOT diagnosis (mean 73.4 months). The overall survival rate was 100%. Recurrence was registered in 4 patients (7.7%). All patients underwent a unilateral salpingo-oophorectomy and all histologic findings corresponded with primary BOTs (3 serous; 1 endometrioid). Higher parity increased while the histological type and stage did not impact recurrence. Average recurrence-free survival was 36.2+/-23.6 months regardless of histological type and stage. Recurrence occurred during the first 3 postoperative years in 75% of cases. Out of 45 women treated with fertility-sparing surgery, 64.4% attempted pregnancy and the pregnancy success rate was 44.8%. Only one pregnancy was conceived by assisted reproduction, while all others were spontaneous. The fertility-sparing treatment in stage I borderline ovarian tumors can be a safe and successful option both in terms of oncologic and reproductive outcomes, regardless of patient and treatment characteristics. Pregnancies after BOT surgery can be achieved with satisfactory rates and adequate outcomes.

Downloads

Download data is not yet available.

References

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D, on behalf of the ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019:30:672-705. https://doi.org/10.1093/annonc/mdz062

Morris CR, Liu L, Rodriguez AO, Cress RD, Snipes K. Epidemiologic features of borderline ovarian tumors in California: a population-based study. Cancer Causes Control. 2013;24:665-74. https://doi.org/10.1007/s10552-013-0145-9

Skirnisdottir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 2008;123:1897-901. https://doi.org/10.1002/ijc.23724

Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, Devesa S. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer. 2004;100:1045-52. https://doi.org/10.1002/cncr.20080

Gershenson DM. Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol. 2017;41:49-59. https://doi.org/10.1016/j.bpobgyn.2016.09.012

Du Bois A, Trillsch F, Mahner S, Heitz F, Harter P. Management of borderline ovarian tumors. Ann Oncol. 2016;27(Suppl1):i20-2. https://doi.org/10.1093/annonc/mdw090

Ancraeynest E, Moerman P, Leunen K, Amant F, Neven P,Vergote I. Fertility preservation is safe for serous borderline ovarian tumors. Int J Gynecol Cancer. 2016;26:1399-406. https://doi.org/10.1097/IGC.0000000000000782

Yilmaz E, Sahin N, Koleli I, Melekoglu R, Tanrikut E, Faydali S, Karaer A, Coskun EI. Retrospective analysis of borderline ovarian tumors: outcomes at a single center. Acta Clin Croat. 2019;58:29-36. https://doi.org/10.20471/acc.2019.58.01.04

Song T, Hun Choi C, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG. Oncologic and reproductive outcomes of cystectomy compared with oophorectomy as a treatment for borderline ovarian tumours. Hum Reprod. 2011;26:2008-14. https://doi.org/10.1093/humrep/der119

Johansen G, Dahm-Kähler P, Staf C, Flöter Rådestad A, Rodriguez-Wallberg KA. Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study. Fertil Steril. 2021;115:157-63. https://doi.org/10.1016/j.fertnstert.2020.07.043

Kumari S, Kumar S, Bhatla N, Mathur S, Thulkar S, Kumar L. Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population. Gynecol Oncol Rep. 2021;36:100756. https://doi.org/10.1016/j.gore.2021.100756

Swanton A, Bankhead CR, Kehoe S. Pregnancy rates after conservative treatment for borderline ovarian tumours: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2007;135:3-7. https://doi.org/10.1016/j.ejogrb.2007.05.011

Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470:125-42. https://doi.org/10.1007/s00428-016-2040-8

Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol Off J U S Can Acad Pathol Inc. 2005;18(Suppl 2):S33-50. https://doi.org/10.1038/modpathol.3800307

Ya Qi, Min Wang, Yuwei Yang, Zhi Zeng, and Yingying Zhou. Analysis of Factors Influencing Relapse and Pregnancy in Patients with Borderline Ovarian Tumors. J Cancer. 2021;12(17):5275-85. https://doi.org/10.7150/jca.56387

Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovarian borderline tumors: a meta-analysis with emphasis on recurrence risk. Eur J Cancer. 2015;51:620-31. https://doi.org/10.1016/j.ejca.2015.01.004

Canlorbe G , Lecointre L , Chauvet P, Azaïs H, Fauvet R , Uzan C. Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Therapeutic Management of Early Stages. Gynecol Obstet Fertil Senol. 2020;48(3):287-303. https://doi.org/10.1016/j.gofs.2020.01.016

Niu L, Tian H, Xu Y, Cao J, Zhang X, Zhang J, Hou J, Lv W, Wang J, Xin L, Dong X, Xu T, Nan Y, Wei H, Chai X, Li N, Ni Y, Shang Y, Zhang L, Zhao Y. Recurrence characteristics and clinicopathological results of borderline ovarian tumors. BMC Womens Health. 2021;31;21(1):134. https://doi.org/10.1186/s12905-021-01263-y

Hannibal Y, Vang R, Junge J. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence and development of ovarian serous carcinoma. Gynecol Oncol. 2017;144:174-80. https://doi.org/10.1016/j.ygyno.2016.11.007

Koskas M, Uzan C, Gouy S, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Morice P. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol. 2011;18:40-8. https://doi.org/10.1245/s10434-010-1293-8

Daraï E, Fauvet R, Uzan C, Gouy S, Duvillard P, Morice P. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update. 2013;19(2):151-66. https://doi.org/10.1093/humupd/dms047

Uzan C, Berretta R, Rolla M, Gouy M, Fauvet R, Darai E, Duillard, Morice P. Menagement and prognosis of endometrioid borderline tumors of the ovary. Surg Oncol. 2012;21(3):178-84. https://doi.org/10.1016/j.suronc.2012.02.002

Delle Marchette M, Ceppi L, Andreano A, Bonazzi CM, Buda A, Grassi T, Giuliani D, Sina F, Lamanna M, Bianchi T, Lissoni AA, Landoni F, Valsecchi MG, Fruscio R. Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery. Eur J Cancer. 2019;111:61-8. https://doi.org/10.1016/j.ejca.2019.01.021

Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril. 2001;75(1):92-6. https://doi.org/10.1016/S0015-0282(00)01633-2

Kim SS. Fertility preservation for women with borderline ovarian tumors: fertility-sparing surgery. Fertil Steril. 2021;115(1):83-4. https://doi.org/10.1016/j.fertnstert.2020.09.129

Van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, Laven JS, Jansen CA, Helmerhorst FM, Cohlen BJ, Willemsen WN, Smeenk JM, Simons AH, van der Veen F, Evers JL, van Dop PA, Macklon NS, Burger CW. Risk of borderline and invasive ovarian tumors after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26(12):3456-65. https://doi.org/10.1093/humrep/der322

Spaan M, van den Belt-Dusebout AW, Lambalk CB, van Boven HH, Schats R, Kortman M, Broekmans FJM, Laven JSE, van Santbrink EJP, Braat DDM, van der Westerlaken LAJ, Cohlen BJ, Cantineau AEP, Smeenk JMJ, van Rumste MM, Goddijn M, van Golde RJT, Meeuwissen PAM, Hamilton CJCM, Ouwens GM, Gerritsma MA, Schaapveld M, Burger CW, van Leeuwen FE. Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology. J Natl Cancer Inst. 2021;113(6):699-709. https://doi.org/10.1093/jnci/djaa163

Fortin A, Hazout A, Thoury A, Alvès K, Bats AS, Dhainaut C, Madelenat P. Assisted reproductive technologies after conservative management of borderline or invasive ovarian tumors. Gynecol Obstet Fertil. 2005;33(7-8):488-97. https://doi.org/10.1016/j.gyobfe.2005.06.010

Cusido M, Fabregas R, Pere BS, Escayola C, Barri PN. Ovulation induction treatment and risk of borderline ovarian tumors. Gynecol Endocrinol. 2007;23(7):373-6. https://doi.org/10.1080/09513590701350341

Palomba S, Zupi E, Russo T, Falbo A, Del Negro S, Manguso F, Marconi D, Tolino A, Zullo F. Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Hum Reprod. 2007;22:578-85. https://doi.org/10.1093/humrep/del381

Palomba S, Falbo A, Del Negro S, Rocca M, Russo T, Cariati F, Annunziata G, Tolino A, Tagliaferri P, Zullo F. Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up. Hum Reprod. 2010;25:1966-72. https://doi.org/10.1093/humrep/deq159

Bourdel N, Huchon C, Abdel Wahab C, Azaïs H, Bendifallah S, Bolze PA, Brun JL, Canlorbe G, Chauvet P, Chereau E, Courbiere B, De La Motte Rouge T, Devouassoux-Shisheboran M, Eymerit-Morin C, Fauvet R, Gauroy E, Gauthier T, Grynberg M, Koskas M, Larouzee E, Lecointre L, Levêque J, Margueritte F, Mathieu D'argent E, Nyangoh-Timoh K, Ouldamer L, Raad J, Raimond E, Ramanah R, Rolland L, Rousset P, Rousset-Jablonski C, Thomassin-Naggara I, Uzan C, Zilliox M, Daraï E. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2021;256:492-501. https://doi.org/10.1016/j.ejogrb.2020.11.045

Downloads

Published

2022-10-05

How to Cite

1.
Likić Lađević I, Nešić D, Stefanović A, Kadija S, Vilendečić Z, Pilić I, Dotlić J, Radojević M, Milošević B, Stefanović K. Oncologic and reproductive outcomes of fertility-sparing surgery for borderline ovarian tumors: first presentation of 10-year experience from a Serbian referral center. Arch Biol Sci [Internet]. 2022Oct.5 [cited 2024Apr.23];74(3):283-90. Available from: https://www.serbiosoc.org.rs/arch/index.php/abs/article/view/7928

Issue

Vol. 74 No. 3 (2022)

Section

Articles

License

Copyright (c) 2022 Ivana Likić Lađević, Dejan Nešić, Aleksandar Stefanović, Saša Kadija, Zoran Vilendečić, Igor Pilić, Jelena Dotlić, Miloš Radojević, Branislav Milošević, Katarina Stefanović

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.

Most read articles by the same author(s)